Commentary - Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups

被引:52
作者
Lehmann, DJ
Williams, J
McBroom, J
Smith, AD
机构
[1] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England
[2] Radcliffe Infirm, OPTIMA, Oxford OX2 6HE, England
[3] Univ Oxford, Dept Stat, Oxford OX1 3TG, England
关键词
apolipoprotein E epsilon 4; butyrylcholinesterase K; meta-analysis; association; case-control; susceptibility;
D O I
10.1016/S0306-4522(01)00464-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In late-onset Alzheimer's disease, there is a puzzling inconsistency between the findings of case-control studies of most proposed risk genes, except apolipoprotein E epsilon4. This inconsistency may stem from the failure to define the genetic and non-genetic interactions that affect the disease association of each particular susceptibility gene. Such interactions will limit the influence of the gene to a 'relevant subset' of vulnerable people, The relevant subsets for many risk genes will be narrow, compared to that of apolipoprotein E epsilon4. Studies may therefore miss the association or even suggest that a risk gene is protective. In these circumstances, the precise composition of a cohort is critical and defining the relevant subset is crucial. We illustrate how such definition may be achieved through meta-analysis. We take as an example the butyrylcholinesterase K variant, whose association with Alzheimer's disease may now be provisionally defined. This analysis leads to the identification of it potentially high-risk group: over 75 year old male carriers of both apolipoprotein E epsilon4 and butyrylcholinesterase K variant. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:541 / 554
页数:14
相关论文
共 104 条
  • [51] Long AD, 1999, GENOME RES, V9, P720
  • [52] LUCOTTE G, 1995, ALZHEIMER RES, V1, P145
  • [53] Pharmacogenomics of neurodegenerative diseases
    Maimone, D
    Dominici, R
    Grimaldi, LME
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 413 (01) : 11 - 29
  • [54] Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese
    Mak, YT
    Chiu, H
    Woo, J
    Kay, R
    Chan, YS
    Hui, E
    Sze, KH
    Lum, C
    Kwok, T
    Pang, CP
    [J]. NEUROLOGY, 1996, 46 (01) : 146 - 149
  • [55] MANTEL N, 1959, J NATL CANCER I, V22, P719
  • [56] APOE GENOTYPES IN AUSTRALIA - ROLES IN EARLY AND LATE-ONSET ALZHEIMERS-DISEASE AND DOWNS-SYNDROME
    MARTINS, RN
    CLARNETTE, R
    FISHER, C
    BROE, GA
    BROOKS, WS
    MONTGOMERY, P
    GANDY, SE
    [J]. NEUROREPORT, 1995, 6 (11) : 1513 - 1516
  • [57] Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E ε4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology
    Mattila, KM
    Rinne, JO
    Röyttä, M
    Laippala, P
    Pietilä, T
    Kalimo, H
    Koivula, T
    Frey, H
    Lehtimäki, T
    [J]. JOURNAL OF MEDICAL GENETICS, 2000, 37 (10) : 766 - 770
  • [58] Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland
    McIlroy, SP
    Crawford, VLS
    Dynan, KB
    McGleenon, BM
    Vahidassr, MD
    Lawson, JT
    Passmore, AP
    [J]. JOURNAL OF MEDICAL GENETICS, 2000, 37 (03) : 182 - 185
  • [59] MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
  • [60] THE CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMERS-DISEASE (CERAD) .2. STANDARDIZATION OF THE NEUROPATHOLOGIC ASSESSMENT OF ALZHEIMERS-DISEASE
    MIRRA, SS
    HEYMAN, A
    MCKEEL, D
    SUMI, SM
    CRAIN, BJ
    BROWNLEE, LM
    VOGEL, FS
    HUGHES, JP
    VANBELLE, G
    BERG, L
    [J]. NEUROLOGY, 1991, 41 (04) : 479 - 486